Chardan Capital Reaffirms Buy Rating for Hyperion DeFi (NASDAQ:HYPD)

Hyperion DeFi (NASDAQ:HYPD)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $7.30 target price on the stock. Chardan Capital’s price objective points to a potential upside of 181.96% from the company’s previous close.

Several other research analysts also recently commented on HYPD. Cantor Fitzgerald lifted their price target on shares of Hyperion DeFi from $4.00 to $6.60 and gave the stock an “overweight” rating in a research note on Wednesday, July 1st. Weiss Ratings upgraded shares of Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th. Finally, Zacks Research raised shares of Hyperion DeFi from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 14th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $6.95.

Hyperion DeFi Price Performance

Shares of Hyperion DeFi stock traded down $0.02 on Tuesday, hitting $2.59. 90,471 shares of the company traded hands, compared to its average volume of 438,189. The company has a current ratio of 1.97, a quick ratio of 1.97 and a debt-to-equity ratio of 0.12. The firm’s 50-day simple moving average is $2.96 and its 200 day simple moving average is $3.36. Hyperion DeFi has a 12-month low of $2.34 and a 12-month high of $15.00. The company has a market cap of $39.25 million, a P/E ratio of -0.26 and a beta of 2.53.

Insider Activity

In other Hyperion DeFi news, insider Hyunsu Jung bought 7,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were bought at an average cost of $3.70 per share, with a total value of $25,900.00. Following the completion of the purchase, the insider directly owned 1,384,676 shares of the company’s stock, valued at $5,123,301.20. This trade represents a 0.51% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 7.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Hyperion DeFi

Several hedge funds have recently made changes to their positions in HYPD. Sanctuary Advisors LLC bought a new position in Hyperion DeFi in the 4th quarter worth $38,000. Nations Financial Group Inc. IA ADV purchased a new position in shares of Hyperion DeFi during the fourth quarter valued at approximately $40,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Hyperion DeFi in the 4th quarter worth approximately $73,000. State Street Corp purchased a new stake in shares of Hyperion DeFi in the 4th quarter worth approximately $92,000. Finally, Investment House LLC bought a new position in Hyperion DeFi during the 4th quarter valued at approximately $166,000. 25.84% of the stock is owned by hedge funds and other institutional investors.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.